• Medipal completed its tender offer for Paltac shares on July 7, 2026.
• Paltac is slated to become a wholly owned subsidiary via a squeeze-out process around August 2026.
• The deal prompted a forecast revision for FY ending March 31, 2027, reflecting higher parent profit as non-controlling interests fall away.
• Medipal expects temporary tender-offer costs in SG&A, with interest expense on acquisition funding booked as non-operating costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medipal Holdings Corporation published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.